Sentences with word «cetuximab»

In a patient population of over 600, though, the hazard ratio for progression - free survival with cetuximab combined with pemetrexed vs pemetrexed alone was 1.0254 (P =.7560), indicating no benefit at all for the combination therapy.

Weidhaas» team analyzed available samples from NRG Oncology RTOG of a randomized phase 3 clinical trial of cetuximab in combination with chemotherapy and radiation therapy.

Researchers have found that people with advanced head and neck squamous cell carcinoma and the KRAS - variant inherited genetic mutation have significantly improved survival when given a short course of the drug cetuximab in combination with standard chemotherapy and radiation.

Finally, yet another phase 3 study — albeit one with less encouraging results — found that the monoclonal antibody drug cetuximab (Erbitux) did not aid people with (potentially curable) early - stage colon cancer if they carried the normal form of the KRAS gene.

Two patients with the specific resistance mutation analyzed achieved partial remissions when treated with a regimen that included the EGFR antibody cetuximab, as predicted by the computer - based structural modeling.

«Colorectal cancer: Second - line cetuximab active beyond progression in quadruple wild - type patients with mcrc.»

«CAPRI is the first study to evaluate cetuximab as second line beyond progression in patients with metastatic colorectal cancer in a randomised phase 2 study.

This likely explains both elevated cancer risk as well as benefit from cetuximab for these individuals.

«Much to our surprise, the trial showed that patients receiving standard therapy compared to those receiving cetuximab with standard therapy had no difference in outcomes,» said study author Dr. Steven Alberts, a professor of oncology at the Mayo Clinic College of Medicine in Rochester, Minn. «It also indicates that disease in earlier stages may be different than diseases in later stages.»

Moreover, LA prevented the prostatic hyperplasia induced by testosterone in rats, triggered apoptosis in colon cancer cells through oxidative stress and improved the sensitization of the EGFR inhibitor cetuximab in KRAS / BRAF mutated colorectal cancer cells.

Analysis of these data in the overall intent to treat population showed an advantage in PFS favouring arm A that did not reach statistical significance; Median PFS was 6.4 months in the FOLFOX plus cetuximab arm A compared to 4.5 months in the FOLFOX arm B (hazard ratio [HR] 0.81; 95 % CI 0.58, 1.12; log - rank test, p = 0.19).

All patients received standard first - line treatment of FOLFIRI plus cetuximab until disease progression or unacceptable toxicity, as previously reported (Ciardiello et al, Annals of Oncology 2014).

Although the sample size was not large, they found a significant benefit of cetuximab treatment for all people with the KRAS - variant.

They found this was on average 14.1 months in the group having chemotherapy and cetuximab compared to 20.5 months in the group having chemotherapy alone.

The researchers found that adding cetuximab to chemotherapy did not help this group of people.

Investigators led by Edward S. Kim, MD, of MD Anderson Cancer Center in Houston, initiated the SELECT trial after earlier, phase II studies showed that cetuximab improved response rates when added to chemotherapy regimens for patients with recurrent or progressive NSCLC.

In mouse cetuximab, the residues lining the hole create a binding location for the peptide.

«Unexpected results in cancer drug trial: Combination of cetuximab, chemo had negative results.»

In the trial patients either received chemotherapy on its own or chemotherapy combined with cetuximab.

Whereas the mutation free, quadruple wild - type population showed significantly prolonged PFS, and improved OS and response rates with second - line cetuximab / FOLFOX, this treatment had the opposite effect upon patients with genetic mutations in the EGFR pathway.

Yet a randomized phase 3 trial was unable to identify those who benefited from cetuximab.

His basic research on growth factors is key to the development of the chemotherapy drug Cetuximab (Erbitux).

Benjamin Solomon, MBBS, PhD, of Peter MacCallum Cancer Centre in Melbourne, said the null results of this study are quite clear, but there remains no obvious way to choose which patients should receive cetuximab.

In the patients with at least one mutation in one of these genes, there was a detrimental effect from FOLFOX plus cetuximab in progression - free survival, response rate and overall survival,» Ciardiello commented.

Prof Fortunato Ciardiello from Seconda Università degli Studi di Napoli, Italy, presented results from the CAPRI - Goim study on the efficacy of cetuximab plus FOLFOX chemotherapy as second - line treatment for patients with mCRC that progressed following FOLFIRI chemotherapy and cetuximab.

Results suggest tumours with multiple wild - type KRAS, NRAS, BRAF and PIK3CA genes are likely to benefit from chemotherapy plus cetuximab and to demonstrate significantly better progression - free survival, response rate and overall survival than with chemotherapy alone,» commented Ciardiello.

Following first - line treatment, patients experiencing disease progression were randomised 1:1 to receive second - line treatment of FOLFOX plus cetuximab (Arm A; n = 74) or sole FOLFOX (Arm B; n = 79).

«An Important finding from this study is those patients with tumours which were multiple wild type — that means no mutation in the KRAS, NRAS, BRAF and PIK3CA genes, were most likely to be EGFR - dependent; in fact, these patients had significantly better progression - free survival when treated with cetuximab and chemotherapy than when treated with chemotherapy alone, hazard ratio 0.56, which was significant (p = 0.025).

Cetuximab / FOLFOX demonstrated significantly longer PFS in patients with quadruple wild - type tumours, while the median PFS in arm A was nearly half that of arm B shorter in patients with a mutation in any of the 4 EGFR - dependant genes.

The first anti-EGFR antibody (cetuximab) for cancer treatment in human medicine was developed by the company Merck.

Companion diagnostics like the ResponseDX test line can identify mutations and guide doctors» decisions about treatments such as cetuximab and panitumumab.

Furthermore, the team found that cetuximab may in fact be working by helping the immune system of people with the KRAS - variant better fight their cancer.

Cetuximab is a monoclonal antibody that was previously shown to be beneficial for these patients when combined with radiation and chemotherapy.

The cetuximab and chemotherapy combination is also used successfully in patients whose disease can not be operated on at all.

They discovered that people with both head and neck squamous cell carcinoma and the KRAS - variant who were treated with standard treatment, but not with cetuximab, had a higher risk of failing treatment and developing metastatic disease, meaning the cancer spreads to distant organs and is incurable.

The New EPOC study, published in The Lancet Oncology and funded by Cancer Research UK, evaluated whether the drug cetuximab and chemotherapy together worked better than chemotherapy alone as a treatment in addition to surgery for people with bowel cancer that had spread to the liver but could be surgically removed.

Cetuximab is already approved by NICE alongside chemotherapy for people who had bowel cancer that had spread to the liver if the oncologist and liver surgeon thought this would enable the patient to have a liver operation.

A Multicenter, Randomized, Open - label, 3 - Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan / Cetuximab or Infusional 5 - Fluorouracil (5 - FU) / Folinic Acid (FA) / Irinotecan (FOLFIRI) / Cetuximab with a Safety Lead - in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E - mutant Metastatic Colorectal Cancer

Agents we are investigating include anti-angiogenic therapeutics (avastin), EGFR inhibitors (cetuximab), BRAF inhibitors and mTOR inhibitors, in colorectal cancer, gastric cancer and cholangiocarcinoma.

Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy - refractory, advanced colorectal cancer.

The CALGB / SWOG 80405 trial randomly assigned 1,137 patients with metastatic or advanced KRAS wild - type colorectal cancer to chemotherapy with FOLFIRI or FOLFOX plus cetuximab or bevacizumab.

Venook previously presented results that showed no difference in progression - free or overall survival with the addition of bevacizumab or cetuximab to first - line FOLFOX or FOLFIRI.

At City of Hope, Williams identified a candidate peptide for creating masked antibodies, synthesized it and crystallized it in complex with cetuximab.

The trial actually enrolled 938 patients with recurrent advanced NSCLC; physicians initially chose pemetrexed or docetaxel for patients, after which patients were randomized to either chemotherapy alone or in addition to a cetuximab regimen.

Most grade 3 or higher adverse events occurred at similar rates between the two groups, though 10.6 % of cetuximab - treated patients had grade 3 or higher rash acneiform, compared with none in the pemetrexed alone group (P <.0001).

Afatinib / cetuximab is another potential option.

The idea of adding the targeted EGFR inhibitor cetuximab (Erbitux) to standard chemotherapy took a hit, as results from the SELECT phase III trial showed no improvement in efficacy when cetuximab was combined with pemetrexed in patients with recurrent or progressive non — small - cell lung cancer (NSCLC).